How to Test Human-Specific Combination Immunotherapies In Vivo

Learn how to evaluate combinations of human-specific checkpoint inhibitors in vivo, with double knock-in humanized drug target mouse models.

Multimodal analysis for human ex vivo studies shows extensive molecular changes from delays in blood processing - ScienceDirect

Pharmaceutics, Free Full-Text

Combined disruption of T cell inflammatory regulators Regnase-1 and Roquin-1 enhances antitumor activity of engineered human T cells

In vivo gene immunotherapy for cancer

Immune cell labelling and tracking: implications for adoptive cell transfer therapies, EJNMMI Radiopharmacy and Chemistry

Frontiers Advances in Human Dendritic Cell-Based Immunotherapy Against Gastrointestinal Cancer

Repurposing Ponatinib as a PD-L1 Inhibitor Revealed by Drug Repurposing Screening and Validation by In Vitro and In Vivo Experiments

Modulating expression of inhibitory and stimulatory immune 'checkpoints' using nanoparticulate-assisted nucleic acid delivery - eBioMedicine

TCR-engineered T cell therapy in solid tumors: State of the art and perspectives

InVivoMAb anti-mouse Ly6G

CD8-Targeted PET Imaging of Tumor-Infiltrating T Cells in Patients with Cancer: A Phase I First-in-Humans Study of 89Zr-Df-IAB22M2C, a Radiolabeled Anti-CD8 Minibody

Enhancing anti-tumour efficacy with immunotherapy combinations - The Lancet

Immunotherapy combination approaches: mechanisms, biomarkers and clinical observations

IJMS, Free Full-Text

Gene therapy approaches against cancer using in vivo and ex vivo gene transfer of interleukin-12